Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer
The presence of disseminated tumor cells (DTC) in the bone marrow (BM) of early breast cancer patients at initial surgery as well as during follow-up predicts an unfavorable outcome. This study aimed to assess whether adjuvant systemic therapy has the ability to eradicate DTC and to determine the cl...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2014-04, Vol.144 (2), p.353-360 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 360 |
|---|---|
| container_issue | 2 |
| container_start_page | 353 |
| container_title | Breast cancer research and treatment |
| container_volume | 144 |
| creator | Gruber, Ines Fehm, Tanja Taran, Florin Andrei Wallwiener, Markus Hahn, Markus Wallwiener, Diethelm Krawzyck, Natalia Hoffmann, Juergen Hartkopf, Andreas Daniel |
| description | The presence of disseminated tumor cells (DTC) in the bone marrow (BM) of early breast cancer patients at initial surgery as well as during follow-up predicts an unfavorable outcome. This study aimed to assess whether adjuvant systemic therapy has the ability to eradicate DTC and to determine the clinical impact of DTC-persistence. Between 12 and 24 months after an initial BM aspiration during primary surgery (BMA1) a second and third bone marrow aspiration (BMA2 and BMA3, respectively) was performed. DTC were identified by immunocytochemistry (pancytokeratin antibody A45-B/B3) and cytomorphology. A total of 190 patients who were DTC-positive at BMA1 were eligible for this retrospective analysis. DTC persisted in 35 of 190 (19 %) patients at BMA2 and in 11 of 71 (16 %) patients at BMA3. DTC-persistence at BMA3 was significantly lower in patients that received adjuvant endocrine therapy (
p
= 0.017). At BMA2, DTC-positive patients were at an increased risk of disease recurrence (HR: 4.17, 95 % CI: 1.51–11.50,
p
= 0.003) and death (HR: 5.02, 95 % CI: 1.156–21.83,
p
= 0.031). At BMA3, the presence of DTC was associated with shorter disease free survival (HR: 3.20, 95 % CI: 1.05–9.78,
p
= 0.010). In conclusion, a majority of initially DTC-positive primary breast cancer patients turned negative during adjuvant treatment. As DTC-persistence predicted an adverse outcome, serial DTC-determination can identify patients that will probably benefit from additional or a switch of adjuvant therapy. |
| doi_str_mv | 10.1007/s10549-014-2853-6 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1506796391</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A380527298</galeid><sourcerecordid>A380527298</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-e576904b74bd8bc4489093deeed2da096c4fe33b707607ff354c04d100daf1f3</originalsourceid><addsrcrecordid>eNp1kl2L1TAQhoMo7nH1B3gjAUG86Tpp89FeLusnLHiz9yFtpntyaJOapMr-e1POUXdFSSCQPO9MZuYl5CWDCwag3iUGgncVMF7VrWgq-YjsmFBNpWqmHpMdMKkq2YI8I89SOgBAp6B7Ss5qLgRvWrkj7r1LCWfnTUZL8zqHSAecpkRN2XQO3uUQnb-lOYSJjuXZ2MP63fhM8x6jWe6o83Qx2aHPif5weU-X6GYT72gf0aRMB-MHjM_Jk9FMCV-cznNy8_HDzdXn6vrrpy9Xl9fVwBXkCoWSHfBe8d62_cB520HXWES0tTXQyYGP2DS9AiVBjWMj-ADcln5YM7KxOSdvj2GXGL6tmLKeXdoqMh7DmjQTIFUnm44V9PVf6CGs0ZfPbZQoqSWIP9StmVA7P4YczbAF1ZdNC6JWddcW6uIfVFm2NHcIHkdX7h8I3twT7NFMeZ_CtGYXfHoIsiM4xJBSxFGf2qsZ6M0G-mgDXWygNxtoWTSvTpWt_Yz2t-LX3AtQH4G0bMPFeK_0_0b9CdAeu6w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505448605</pqid></control><display><type>article</type><title>Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Gruber, Ines ; Fehm, Tanja ; Taran, Florin Andrei ; Wallwiener, Markus ; Hahn, Markus ; Wallwiener, Diethelm ; Krawzyck, Natalia ; Hoffmann, Juergen ; Hartkopf, Andreas Daniel</creator><creatorcontrib>Gruber, Ines ; Fehm, Tanja ; Taran, Florin Andrei ; Wallwiener, Markus ; Hahn, Markus ; Wallwiener, Diethelm ; Krawzyck, Natalia ; Hoffmann, Juergen ; Hartkopf, Andreas Daniel</creatorcontrib><description>The presence of disseminated tumor cells (DTC) in the bone marrow (BM) of early breast cancer patients at initial surgery as well as during follow-up predicts an unfavorable outcome. This study aimed to assess whether adjuvant systemic therapy has the ability to eradicate DTC and to determine the clinical impact of DTC-persistence. Between 12 and 24 months after an initial BM aspiration during primary surgery (BMA1) a second and third bone marrow aspiration (BMA2 and BMA3, respectively) was performed. DTC were identified by immunocytochemistry (pancytokeratin antibody A45-B/B3) and cytomorphology. A total of 190 patients who were DTC-positive at BMA1 were eligible for this retrospective analysis. DTC persisted in 35 of 190 (19 %) patients at BMA2 and in 11 of 71 (16 %) patients at BMA3. DTC-persistence at BMA3 was significantly lower in patients that received adjuvant endocrine therapy (
p
= 0.017). At BMA2, DTC-positive patients were at an increased risk of disease recurrence (HR: 4.17, 95 % CI: 1.51–11.50,
p
= 0.003) and death (HR: 5.02, 95 % CI: 1.156–21.83,
p
= 0.031). At BMA3, the presence of DTC was associated with shorter disease free survival (HR: 3.20, 95 % CI: 1.05–9.78,
p
= 0.010). In conclusion, a majority of initially DTC-positive primary breast cancer patients turned negative during adjuvant treatment. As DTC-persistence predicted an adverse outcome, serial DTC-determination can identify patients that will probably benefit from additional or a switch of adjuvant therapy.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-014-2853-6</identifier><identifier>PMID: 24554386</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adjuvant treatment ; Bone marrow ; Bone Marrow - pathology ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Cancer ; Cancer research ; Cancer therapies ; Cell Line, Tumor ; Chemotherapy, Adjuvant ; Clinical Trial ; Disease-Free Survival ; Female ; Health aspects ; Humans ; Immunohistochemistry ; MCF-7 Cells ; Medicine ; Medicine & Public Health ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - pathology ; Neoplastic Cells, Circulating - pathology ; Oncology ; Prognosis ; Retrospective Studies ; Tumors</subject><ispartof>Breast cancer research and treatment, 2014-04, Vol.144 (2), p.353-360</ispartof><rights>Springer Science+Business Media New York 2014</rights><rights>COPYRIGHT 2014 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-e576904b74bd8bc4489093deeed2da096c4fe33b707607ff354c04d100daf1f3</citedby><cites>FETCH-LOGICAL-c470t-e576904b74bd8bc4489093deeed2da096c4fe33b707607ff354c04d100daf1f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-014-2853-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-014-2853-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,782,786,27931,27932,41495,42564,51326</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24554386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gruber, Ines</creatorcontrib><creatorcontrib>Fehm, Tanja</creatorcontrib><creatorcontrib>Taran, Florin Andrei</creatorcontrib><creatorcontrib>Wallwiener, Markus</creatorcontrib><creatorcontrib>Hahn, Markus</creatorcontrib><creatorcontrib>Wallwiener, Diethelm</creatorcontrib><creatorcontrib>Krawzyck, Natalia</creatorcontrib><creatorcontrib>Hoffmann, Juergen</creatorcontrib><creatorcontrib>Hartkopf, Andreas Daniel</creatorcontrib><title>Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>The presence of disseminated tumor cells (DTC) in the bone marrow (BM) of early breast cancer patients at initial surgery as well as during follow-up predicts an unfavorable outcome. This study aimed to assess whether adjuvant systemic therapy has the ability to eradicate DTC and to determine the clinical impact of DTC-persistence. Between 12 and 24 months after an initial BM aspiration during primary surgery (BMA1) a second and third bone marrow aspiration (BMA2 and BMA3, respectively) was performed. DTC were identified by immunocytochemistry (pancytokeratin antibody A45-B/B3) and cytomorphology. A total of 190 patients who were DTC-positive at BMA1 were eligible for this retrospective analysis. DTC persisted in 35 of 190 (19 %) patients at BMA2 and in 11 of 71 (16 %) patients at BMA3. DTC-persistence at BMA3 was significantly lower in patients that received adjuvant endocrine therapy (
p
= 0.017). At BMA2, DTC-positive patients were at an increased risk of disease recurrence (HR: 4.17, 95 % CI: 1.51–11.50,
p
= 0.003) and death (HR: 5.02, 95 % CI: 1.156–21.83,
p
= 0.031). At BMA3, the presence of DTC was associated with shorter disease free survival (HR: 3.20, 95 % CI: 1.05–9.78,
p
= 0.010). In conclusion, a majority of initially DTC-positive primary breast cancer patients turned negative during adjuvant treatment. As DTC-persistence predicted an adverse outcome, serial DTC-determination can identify patients that will probably benefit from additional or a switch of adjuvant therapy.</description><subject>Adjuvant treatment</subject><subject>Bone marrow</subject><subject>Bone Marrow - pathology</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Cell Line, Tumor</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical Trial</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>MCF-7 Cells</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kl2L1TAQhoMo7nH1B3gjAUG86Tpp89FeLusnLHiz9yFtpntyaJOapMr-e1POUXdFSSCQPO9MZuYl5CWDCwag3iUGgncVMF7VrWgq-YjsmFBNpWqmHpMdMKkq2YI8I89SOgBAp6B7Ss5qLgRvWrkj7r1LCWfnTUZL8zqHSAecpkRN2XQO3uUQnb-lOYSJjuXZ2MP63fhM8x6jWe6o83Qx2aHPif5weU-X6GYT72gf0aRMB-MHjM_Jk9FMCV-cznNy8_HDzdXn6vrrpy9Xl9fVwBXkCoWSHfBe8d62_cB520HXWES0tTXQyYGP2DS9AiVBjWMj-ADcln5YM7KxOSdvj2GXGL6tmLKeXdoqMh7DmjQTIFUnm44V9PVf6CGs0ZfPbZQoqSWIP9StmVA7P4YczbAF1ZdNC6JWddcW6uIfVFm2NHcIHkdX7h8I3twT7NFMeZ_CtGYXfHoIsiM4xJBSxFGf2qsZ6M0G-mgDXWygNxtoWTSvTpWt_Yz2t-LX3AtQH4G0bMPFeK_0_0b9CdAeu6w</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Gruber, Ines</creator><creator>Fehm, Tanja</creator><creator>Taran, Florin Andrei</creator><creator>Wallwiener, Markus</creator><creator>Hahn, Markus</creator><creator>Wallwiener, Diethelm</creator><creator>Krawzyck, Natalia</creator><creator>Hoffmann, Juergen</creator><creator>Hartkopf, Andreas Daniel</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20140401</creationdate><title>Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer</title><author>Gruber, Ines ; Fehm, Tanja ; Taran, Florin Andrei ; Wallwiener, Markus ; Hahn, Markus ; Wallwiener, Diethelm ; Krawzyck, Natalia ; Hoffmann, Juergen ; Hartkopf, Andreas Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-e576904b74bd8bc4489093deeed2da096c4fe33b707607ff354c04d100daf1f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adjuvant treatment</topic><topic>Bone marrow</topic><topic>Bone Marrow - pathology</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Cell Line, Tumor</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical Trial</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>MCF-7 Cells</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gruber, Ines</creatorcontrib><creatorcontrib>Fehm, Tanja</creatorcontrib><creatorcontrib>Taran, Florin Andrei</creatorcontrib><creatorcontrib>Wallwiener, Markus</creatorcontrib><creatorcontrib>Hahn, Markus</creatorcontrib><creatorcontrib>Wallwiener, Diethelm</creatorcontrib><creatorcontrib>Krawzyck, Natalia</creatorcontrib><creatorcontrib>Hoffmann, Juergen</creatorcontrib><creatorcontrib>Hartkopf, Andreas Daniel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gruber, Ines</au><au>Fehm, Tanja</au><au>Taran, Florin Andrei</au><au>Wallwiener, Markus</au><au>Hahn, Markus</au><au>Wallwiener, Diethelm</au><au>Krawzyck, Natalia</au><au>Hoffmann, Juergen</au><au>Hartkopf, Andreas Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>144</volume><issue>2</issue><spage>353</spage><epage>360</epage><pages>353-360</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>The presence of disseminated tumor cells (DTC) in the bone marrow (BM) of early breast cancer patients at initial surgery as well as during follow-up predicts an unfavorable outcome. This study aimed to assess whether adjuvant systemic therapy has the ability to eradicate DTC and to determine the clinical impact of DTC-persistence. Between 12 and 24 months after an initial BM aspiration during primary surgery (BMA1) a second and third bone marrow aspiration (BMA2 and BMA3, respectively) was performed. DTC were identified by immunocytochemistry (pancytokeratin antibody A45-B/B3) and cytomorphology. A total of 190 patients who were DTC-positive at BMA1 were eligible for this retrospective analysis. DTC persisted in 35 of 190 (19 %) patients at BMA2 and in 11 of 71 (16 %) patients at BMA3. DTC-persistence at BMA3 was significantly lower in patients that received adjuvant endocrine therapy (
p
= 0.017). At BMA2, DTC-positive patients were at an increased risk of disease recurrence (HR: 4.17, 95 % CI: 1.51–11.50,
p
= 0.003) and death (HR: 5.02, 95 % CI: 1.156–21.83,
p
= 0.031). At BMA3, the presence of DTC was associated with shorter disease free survival (HR: 3.20, 95 % CI: 1.05–9.78,
p
= 0.010). In conclusion, a majority of initially DTC-positive primary breast cancer patients turned negative during adjuvant treatment. As DTC-persistence predicted an adverse outcome, serial DTC-determination can identify patients that will probably benefit from additional or a switch of adjuvant therapy.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24554386</pmid><doi>10.1007/s10549-014-2853-6</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2014-04, Vol.144 (2), p.353-360 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1506796391 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adjuvant treatment Bone marrow Bone Marrow - pathology Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Breast Neoplasms - surgery Cancer Cancer research Cancer therapies Cell Line, Tumor Chemotherapy, Adjuvant Clinical Trial Disease-Free Survival Female Health aspects Humans Immunohistochemistry MCF-7 Cells Medicine Medicine & Public Health Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neoplastic Cells, Circulating - pathology Oncology Prognosis Retrospective Studies Tumors |
| title | Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T15%3A28%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Disseminated%20tumor%20cells%20as%20a%20monitoring%20tool%20for%20adjuvant%20therapy%20in%20patients%20with%20primary%20breast%20cancer&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Gruber,%20Ines&rft.date=2014-04-01&rft.volume=144&rft.issue=2&rft.spage=353&rft.epage=360&rft.pages=353-360&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-014-2853-6&rft_dat=%3Cgale_proqu%3EA380527298%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505448605&rft_id=info:pmid/24554386&rft_galeid=A380527298&rfr_iscdi=true |